Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study Meeting Abstract
| Authors: | Ramalingam, S. S.; Zhou, C.; Kim, T. M.; Kim, S. W.; Yang, J. C. H.; Riely, G. J.; Mekhail, T.; Nguyen, D.; Campelo, M. R. G.; Felip, E.; Vincent, S.; Jin, S.; Bunn, V.; Lin, J.; Lin, H. M.; Mehta, M.; Janne, P. A. |
| Abstract Title: | Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120604308 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.9014 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9014 -- Source: Wos |
